Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition - Summary - MDSpire

Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition

  • By

  • Yijia Li

  • Michael B Townsend

  • Shanshan Li

  • Quinn E Testa

  • Tom Medvec

  • Elizabeth A Thompson

  • Frank J Palella

  • Matthew J Mimiaga

  • James B Brock

  • Maria L Alcaide

  • Anandi N Sheth

  • Michelle Floris-Moore

  • Aruna Chandran

  • Audrey L French

  • Phyllis C Tien

  • Daniel J Merenstein

  • Michael Augenbraun

  • Anjali Sharma

  • Caitlin A Moran

  • Charles R Rinaldo

  • Bernard J C Macatangay

  • Panayampalli S Satheshkumar

  • Ken S Ho

  • August 14, 2025

  • 0 min

Share

Objective:

To evaluate the serologic response to MVA-BN vaccination against mpox in older individuals with or at risk for HIV.

Key Findings:
  • MVA-BN induced sustained IgG levels regardless of HIV status, lasting up to 1 year.
  • Higher IgG levels were correlated with birth before 1973, indicating potential age-related immune response.
  • MVA-BN-unvaccinated individuals with HIV had lower IgG levels compared to those without HIV.
Interpretation:

The study suggests that MVA-BN vaccination is effective in eliciting a robust immune response in older adults, including those with HIV, which may inform vaccination strategies.

Limitations:
  • Small sample size limits generalizability and may introduce biases.
  • Lack of long-term follow-up data beyond 1 year restricts understanding of sustained immunity.
Conclusion:

This study is among the first to assess anti-orthopoxvirus antibodies in an older, vulnerable population stratified by HIV status, highlighting the importance of MVA-BN vaccination in public health.

Original Source(s)

Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition

  • by Yijia Li, Michael B Townsend, Shanshan Li, Quinn E Testa, Tom Medvec, Elizabeth A Thompson, Frank J Palella, Matthew J Mimiaga, James B Brock, Maria L Alcaide, Anandi N Sheth, Michelle Floris-Moore, Aruna Chandran, Audrey L French, Phyllis C Tien, Daniel J Merenstein, Michael Augenbraun, Anjali Sharma, Caitlin A Moran, Charles R Rinaldo, Bernard J C Macatangay, Panayampalli S Satheshkumar, Ken S Ho

  • August 14, 2025

Related Content

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.